Free Newsletter
FEATURES >> The most interesting logos in Pharma
NIH unveils new asthma guidelines
New asthma treatment guidelines could be good news for drug companies. The government advises better day-to-day control of the disease--and that probably means more widespread use of inhaled corticosteroid drugs such as Flovent (GlaxoSmithKline), Azmacort (Sanofi-Aventis), and Pulmicort (AstraZeneca).
For patients with severe asthma, the National Institutes of Health report also recommends Omalizumab, a Genentech/Novartis drug sold under the brand name Xolair, which targets antibodies that can cause asthma symptoms.
- see the new NIH guidelines
- read the Washington Post's take
- and check out this piece on AstraZeneca's asthma drugs
Related Articles:
Scientists find link between colds and asthma attacks. Report
FDA rejects GSK's Advair for COPD. Report
NIH budget cuts cause alarm in research circles. Report
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities



SHARE
WITH: